002286SZSE

Announcement on Seeking Shareholder Authorization for Board to Handle Simplified Procedure Private Placement of Shares

Baolingbao Co., Ltd.·

✨ AI Summary

Baolingbao Biotechnology Co., Ltd. proposes to seek shareholder approval for the board of directors to handle a simplified procedure private placement of shares. The total fundraising will not exceed RMB 300 million, not exceeding 20% of the net assets at the end of the most recent year. The authorization period is from the 2025 annual shareholder meeting to the 2026 annual shareholder meeting. This aims to support sustainable development.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_documentSign In to Upgrade

Stock Code: 002286 Stock Abbreviation: Baolingbao Announcement Number: 2026-017

Baolingbao Biotechnology Co., Ltd.

Announcement on Seeking Shareholder Authorization for Board to Handle Simplified Procedure Private Placement of Shares

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or major omissions.

Baolingbao Biotechnology Co., Ltd. (hereinafter referred to as the "Company") held the 16th meeting of the Sixth Board of Directors on April 23, 2026, and deliberated and passed the "Proposal on Seeking Shareholder Authorization for the Board of Directors to Handle Simplified Procedure Private Placement of Shares." In accordance with the "Administrative Measures for the Registration of Securities Offerings by Listed Companies," the "Shenzhen Stock Exchange Stock Listing Review Rules," and the "Shenzhen Stock Exchange Implementation Rules for Securities Issuance and Underwriting Business," etc., the Company's Board of Directors proposes to seek authorization from the 2025 Annual Shareholders' Meeting for the Board of Directors to handle a simplified procedure private placement of shares to specific objects, with a total fundraising amount not exceeding RMB 300 million and not exceeding 20% of the net assets at the end of the most recent year. The authorization period shall be from the date of approval by the 2025 Annual Shareholders' Meeting to the date of the 2026 Annual Shareholders' Meeting. The above matters are subject to shareholder approval. The relevant matters are hereby announced as follows:

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.

Notes & Comments

Sign in to leave a comment or private note.

Loading…